{"component": "definition", "props": {"groups": [{"samples": [{"hash": "4uqPe6mxh0k", "uri": "/contracts/4uqPe6mxh0k#active-agent", "label": "Feasibility, Development and Commercialization Agreement (Auto Search Cars, Inc.)", "score": 21.4709103354, "published": true}, {"hash": "87sElADY7D7", "uri": "/contracts/87sElADY7D7#active-agent", "label": "Feasibility, Development and Commercialization Agreement (Auto Search Cars, Inc.)", "score": 21.3997262149, "published": true}, {"hash": "eyAyRL64ayA", "uri": "/contracts/eyAyRL64ayA#active-agent", "label": "Feasibility, Development and Commercialization Agreement (Auto Search Cars, Inc.)", "score": 21.3175906913, "published": true}], "snippet": "means leuprolide acetate.", "size": 5, "snippet_links": [], "hash": "f49c1758fb14abf151fcb76207484d47", "id": 1}, {"samples": [{"hash": "dR3vQTZ1OjY", "uri": "/contracts/dR3vQTZ1OjY#active-agent", "label": "License and Commercialization Agreement (Otonomy, Inc.)", "score": 25.5229295003, "published": true}, {"hash": "i7tEJHG8eNk", "uri": "/contracts/i7tEJHG8eNk#active-agent", "label": "License and Commercialization Agreement (Otonomy, Inc.)", "score": 25.462696783, "published": true}, {"hash": "6vwAJe2gVnv", "uri": "https://investors.otonomy.com/static-files/f448add2-71be-4435-a1cc-9edeb4131dde", "label": "investors.otonomy.com", "score": 9.9637234771, "published": false}], "snippet": "means Gacyclidine, as well as each of the separate diasteriomers comprising Gacyclidine, together with all salt forms, solvates and esters of any of the foregoing, in each case to the extent claimed or otherwise disclosed in the DURECT Patent Rights.", "size": 3, "snippet_links": [{"key": "the-foregoing", "type": "definition", "offset": [149, 162]}, {"key": "each-case", "type": "definition", "offset": [167, 176]}, {"key": "to-the-extent", "type": "clause", "offset": [177, 190]}, {"key": "durect-patent-rights", "type": "definition", "offset": [229, 249]}], "hash": "8b923deebe4979ac584f99ecc8510e51", "id": 2}, {"samples": [{"hash": "1esWKbxSSRh", "uri": "/contracts/1esWKbxSSRh#active-agent", "label": "Asset Transfer Agreement (Otonomy, Inc.)", "score": 25.5229295003, "published": true}, {"hash": "6Rq9GDkuu1w", "uri": "/contracts/6Rq9GDkuu1w#active-agent", "label": "Asset Transfer Agreement (Otonomy, Inc.)", "score": 25.462696783, "published": true}, {"hash": "6vwAJe2gVnv", "uri": "https://investors.otonomy.com/static-files/f448add2-71be-4435-a1cc-9edeb4131dde", "label": "investors.otonomy.com", "score": 9.9637234771, "published": false}], "snippet": "means Gacyclidine, as well as each of the separate diasteriomers comprising Gacyclidine, together with all salt forms, solvates and esters of any of the foregoing.", "size": 3, "snippet_links": [{"key": "the-foregoing", "type": "definition", "offset": [149, 162]}], "hash": "e7882aa445b6c3b9ef44bdf9894e865e", "id": 3}, {"samples": [{"hash": "1SlnrqjJApq", "uri": "/contracts/1SlnrqjJApq#active-agent", "label": "Development and License Agreement (Durect Corp)", "score": 21.8480492813, "published": true}, {"hash": "jKggptJicYK", "uri": "https://investors.durect.com/static-files/e3c72452-4ac6-44fc-8dac-e71c34831024", "label": "investors.durect.com", "score": 7.7405886379, "published": false}], "snippet": "means risperidone [* * *].", "size": 3, "snippet_links": [], "hash": "b73d58a697f2dad1d9ed2d49887b922f", "id": 4}, {"samples": [{"hash": "aWzXTRlnrwN", "uri": "/contracts/aWzXTRlnrwN#active-agent", "label": "License Agreement (Nupathe Inc.)", "score": 21.5667351129, "published": true}, {"hash": "j06N2R6uYkU", "uri": "/contracts/j06N2R6uYkU#active-agent", "label": "License Agreement (Nupathe Inc.)", "score": 21.4517453799, "published": true}], "snippet": "means the non-ergoline dopamine agonist known as ropinirole (including the hydrochloride salt and free base).", "size": 2, "snippet_links": [{"key": "the-non", "type": "clause", "offset": [6, 13]}], "hash": "bfd1c97c8722912ed6bd1cb1b009e333", "id": 5}, {"samples": [{"hash": "iwPTDrywX4j", "uri": "/contracts/iwPTDrywX4j#active-agent", "label": "Agreement for Antibody Discovery and Development (Omeros Corp)", "score": 21.0, "published": true}, {"hash": "h6hWqVzmB38", "uri": "/contracts/h6hWqVzmB38#active-agent", "label": "Agreement for Antibody Discovery and Development (Omeros Corp)", "score": 21.0, "published": true}], "snippet": "means a biological or pharmaceutical agent that provides a desired therapeutic effect when administered in a biological or pharmaceutical drug product, and does not include carriers, binders, fillers, solubilizers, stabilizers, buffers, acidifying agents or other excipients that do not exert therapeutic effect.", "size": 2, "snippet_links": [{"key": "pharmaceutical-agent", "type": "clause", "offset": [22, 42]}, {"key": "drug-product", "type": "definition", "offset": [138, 150]}], "hash": "34e118239158074602cf82ce10bd33f6", "id": 6}, {"samples": [{"hash": "5CPNalxKc7o", "uri": "/contracts/5CPNalxKc7o#active-agent", "label": "License Agreement (Edge Therapeutics, Inc.)", "score": 26.6153319644, "published": true}, {"hash": "7AMrjHXQOMx", "uri": "/contracts/7AMrjHXQOMx#active-agent", "label": "License Agreement (Edge Therapeutics, Inc.)", "score": 25.3778234086, "published": true}], "snippet": "means (a) nimodipine, (b) **, or (c) any of the Other Active Agents for which Edge has obtained rights to in accordance with Section 5.4.", "size": 2, "snippet_links": [{"key": "other-active", "type": "definition", "offset": [48, 60]}, {"key": "in-accordance-with", "type": "definition", "offset": [106, 124]}, {"key": "section-54", "type": "clause", "offset": [125, 136]}], "hash": "ff544d400063caa58a843a4abc63b9b0", "id": 7}, {"samples": [{"hash": "d99WrsgUlm1", "uri": "/contracts/d99WrsgUlm1#active-agent", "label": "Commercial Agreement (Achieve Life Sciences, Inc.)", "score": 28.8548939083, "published": true}], "snippet": "means the active pharmaceutical ingredient (-)-Cytisine, as derived from plant genera, including but not limited to Laburnum and Cytisus of the family Fabaceae, and any intermediates, salts and esters thereof.", "size": 2, "snippet_links": [{"key": "active-pharmaceutical-ingredient", "type": "definition", "offset": [10, 42]}, {"key": "not-limited", "type": "clause", "offset": [101, 112]}, {"key": "the-family", "type": "clause", "offset": [140, 150]}], "hash": "4e563d501f04b7aa7215d7489c1aba9d", "id": 8}, {"samples": [{"hash": "fgwCsr6FY06", "uri": "https://patentimages.storage.googleapis.com/e2/2e/1b/77efaa365a037a/WO2018140472A1.pdf", "label": "patentimages.storage.googleapis.com", "score": 9.2765229295, "published": false}], "snippet": "as used herein means an additive that produces an intended effect in an environment external to a fibrous element and/or a particle and/or a fibrous structure comprising a fibrous element of the present disclosure, such as when the fibrous element and/or a particle and/or fibrous structure is exposed to conditions of intended use of the fibrous element and/or a particle and/or a fibrous structure comprising a fibrous element. In one example, an active agent comprises an additive that treats a surface, such as a hard surface (i.e., kitchen countertops, bath tubs, toilets, toilet bowls, sinks, floors, walls, teeth, cars, windows, mirrors, dishes) and/or a soft surface (i.e., fabric, hair, skin, carpet, crops, plants,). In another example, an active agent comprises an additive that creates a chemical reaction (i.e., foaming, fizzing, effervescing, coloring, warming, cooling, lathering, disinfecting and/or clarifying and/or chlorinating, such as in clarifying water and/or disinfecting water and/or chlorinating water). In yet another example, an active agent comprises an additive that treats an environment (i.e., deodorizes, purifies, perfumes air). In one example, the active agent is formed in situ, such as during the formation of the fibrous element and/or particle containing the active agent, for example the fibrous element and/or particle may comprise a water- soluble polymer (e.g., starch) and a surfactant (e.g., anionic surfactant), which may create a polymer complex or coacervate that functions as the active agent used to treat fabric surfaces.", "size": 1, "snippet_links": [{"key": "intended-effect", "type": "clause", "offset": [50, 65]}, {"key": "fibrous-structure", "type": "definition", "offset": [141, 158]}, {"key": "exposed-to", "type": "definition", "offset": [294, 304]}, {"key": "conditions-of", "type": "clause", "offset": [305, 318]}, {"key": "intended-use", "type": "clause", "offset": [319, 331]}, {"key": "hard-surface", "type": "definition", "offset": [517, 529]}, {"key": "chemical-reaction", "type": "clause", "offset": [800, 817]}, {"key": "formation-of-the", "type": "clause", "offset": [1234, 1250]}, {"key": "for-example", "type": "clause", "offset": [1312, 1323]}], "hash": "165e6924d700e3a4344dff05ad9ddfa1", "id": 9}, {"samples": [{"hash": "20wcow606Vs", "uri": "/contracts/20wcow606Vs#active-agent", "label": "Exclusive License Agreement (Oncogenex Pharmaceuticals, Inc.)", "score": 28.3347022587, "published": true}], "snippet": "means Cytisine or the active pharmaceutical ingredients in the product branded by Sopharma as Tabex including Cytisine, as well as Intermediates, salts, esters and pharmaceutical compositions containing Cytisine or its bioequivalent.", "size": 1, "snippet_links": [{"key": "active-pharmaceutical-ingredients", "type": "definition", "offset": [22, 55]}, {"key": "the-product", "type": "clause", "offset": [59, 70]}], "hash": "974bccc7efcea7e69b94ebcfb78d6386", "id": 10}], "next_curs": "ClkSU2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjULEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIVYWN0aXZlLWFnZW50IzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means leuprolide acetate.", "size": 33, "title": "Active Agent", "id": "active-agent", "examples": ["SBS shall maintain in such facilities adequate and segregated (if required) holding accommodations for the Product, the <strong>Active Agent</strong>, and the excipients, packaging components, and other items used in Manufacturing the Product in accordance with the Product Specifications, the Regulatory Approvals and the Manufacturing Process, GMP and all other Applicable Law.", "Charges for reimbursement of purchases of <strong>Active Agent</strong> by SBS in connection with the performance of the Feasibility Activities and the Development Activities shall be invoiced separately from time to time and shall be paid by Voyager within thirty (30) days of receipt thereof.", "SBS estimates that approximately [**] of <strong>Active Agent</strong> will be required for the completion of the Feasibility Activities.", "Pavlakis 2263705 Canada Department Of Health And Human Services App 8/19/1996 8/1/1997 Novel Sandwich Liposome Complexes Comprising A Biologically <strong>Active Agent</strong> N.", "In the event the feasibility of using ** or ** (each, an \u201cOther <strong>Active Agent</strong>\u201d) with the Formulation in the Field is demonstrated under a separate agreement between SurModics and Edge, then the meaning of the term <strong>Active Agent</strong> shall be expanded to include such Other <strong>Active Agent</strong> (or both, as the case may be) (the \u201c<strong>Active Agent</strong> Option\u201d).", "Upon termination of this Agreement, Evonik will return all unused <strong>Active Agent</strong> to Customer, if requested to do so, within *** days after termination, or otherwise will dispose of the <strong>Active Agent</strong> at Customer\u2019s direction and expense (which shall be reasonable and documented).", "The <strong>Active Agent</strong> Option shall be time limited for a ** period beginning with the Effective Date of this Agreement.", "Edge may extend the <strong>Active Agent</strong> Option for an additional ** period subject to payment of an extension fee of ** U.S. Dollars on or prior to the expiration of the initial ** period.", "If at any time legal restrictions prevent the prompt remittance of part or all of payments owed hereunder with respect to any country in the world where an <strong>Active Agent</strong> Product is sold, payment shall be made through any lawful means or methods that may be available as the Parties shall reasonably determine.", "In addition, Merck shall grant Nitec Pharma access to all of its know-how obtained with respect to the <strong>Active Agent</strong>."], "related": [["revolving-administrative-agent", "Revolving Administrative Agent", "Revolving Administrative Agent"], ["effective-age", "Effective age", "Effective age"], ["administrative-agent", "Administrative Agent", "Administrative Agent"], ["canadian-administrative-agent", "Canadian Administrative Agent", "Canadian Administrative Agent"], ["administrative-agents", "Administrative Agents", "Administrative Agents"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}